Results 141 to 150 of about 66,239 (358)

Catheter Ablation Is Associated With a Decrease in Major Adverse Cardiovascular Events and All‐Cause Mortality in Patients With Atrial Fibrillation and Obstructive Sleep Apnea

Journal of Cardiovascular Electrophysiology, EarlyView.
ABSTRACT Introduction Obstructive sleep apnea (OSA) is a common risk factor for the development and progression of atrial fibrillation (AF). Whether catheter ablation for AF management in patients with coexisting OSA yields survival benefit remains unclear.
Ghassan Bidaoui, Christian Massad, Joe Abi‐Rached, Ahmed Abdelmaksoud, Eman Toraih, Michel Abou‐Khalil, Mayana Bsoul, Montaser Atasi, Amitabh Pandey, Nassir Marrouche, and other members of the TRIAD Team, Yara Menassa, Han Feng, Swati Rao, Chanho Lim, Ala' Assaf, Hadi Younes   +16 more
wiley   +1 more source

Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation:Contemporary findings in real-life Danish patients [PDF]

, 2017
Background The nonvitamin K antagonist oral anticoagulants have recently become available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on real‐life patient experience, including bleeding ...
Evans, David, Fosbøl, Emil Loldrup, Gislason, Gunnar Hilmar, Hansen, Morten Lock, Harboe, Louise, Lamberts, Morten, Lefevre, Cinira, Olesen, Jonas Bjerring, Staerk, Laila   +8 more
core   +3 more sources

Role of rivaroxaban after TAVI [PDF]

Nature Reviews Cardiology, 2019
Results of the GALILEO trial presented at the AHA Scientific Sessions 2019 indicate that a strategy with rivaroxaban 10 mg daily is associated with a higher risk of death or thromboembolic events and a higher risk of bleeding than an antiplatelet-based strategy.
openaire   +2 more sources

Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial.

JAMA Neurology, 2019
Importance The NAVIGATE ESUS randomized clinical trial found that 15 mg of rivaroxaban per day does not reduce stroke compared with aspirin in patients with embolic stroke of undetermined source (ESUS); however, it substantially reduces stroke risk in ...
J. Healey, D. Gladstone, Balakumar Swaminathan, J. Eckstein, H. Mundl, A. Epstein, K. Haeusler, R. Mikulík, S. Kasner, D. Toni, A. Arauz, G. Ntaios, G. Hankey, K. Perera, J. Pagola, A. Shuaib, H. Lutsep, Xiaomeng Yang, S. Uchiyama, M. Endres, S. Coutts, M. Karlinski, A. Członkowska, C. Molina, G. Santo, S. Berkowitz, R. Hart, S. Connolly   +27 more
semanticscholar   +1 more source

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation

Therapeutics and Clinical Risk Management, 2014
Alexander GG Turpie Department of Medicine, McMaster University, Hamilton, ONT, Canada Abstract: Atrial fibrillation (AF) is the most common cardiac arrhythmia in the developed world and is associated with a fivefold increase in the risk of stroke ...
Turpie AGG
doaj  

Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study

Pharmaceuticals, 2012
Dual antiplatelet therapy with acetylsalicylic acid and a thienopyridine, such as clopidogrel, is effective for the secondary prevention of cardiovascular events in patients with acute coronary syndrome, but there is still a substantial residual risk of ...
Michael Becka, Wolfgang Mück, Stephan Schwers, Dagmar Kubitza   +3 more
doaj   +1 more source

Physiologically‐Based Pharmacokinetic Modeling for the Prediction of a Drug–Drug Interaction of Combined Effects on P‐glycoprotein and Cytochrome P450 3A

CPT: Pharmacometrics & Systems Pharmacology, 2020
Direct oral anticoagulants, such as apixaban and rivaroxaban, are important for the treatment and prophylaxis of venous thromboembolism and to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Yukio Otsuka, Mary P. Choules, Peter L. Bonate, Kanji Komatsu   +3 more
doaj   +1 more source

Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. [PDF]

, 2018
Aims: In Europe, the approved rivaroxaban dose for stroke prevention in patients with atrial fibrillation is 20 mg once daily (od), with 15 mg od recommended in patients with creatinine clearance [CrCl] 15-49 mL/min.
Bayer, Camm, Camm, Camm, Chugh, Connolly, Giugliano, Granger, Kirchhof, Patel, Ruff, Schulman, Steinberg, Steinberg   +13 more
core   +2 more sources

Delphi Consensus Among French Obesity Experts on Clinical Recommendations for Drug Prescription in Patients With Severe Obesity

Obesity Reviews, EarlyView.
ABSTRACT Introduction Although the physiologic alterations seen in obesity often affect the pharmacokinetics and pharmacodynamics of drugs, most clinical trials do not consider these aspects specifically for this population. To date, there is no list of potentially inappropriate medications for patients living with obesity. The aim of this study was to
Sarah Berdot, Germain Perrin, Emmanuel Disse, Armelle Arnoux, Eric Bertin, Anne‐Laure Borel, Marie‐Claude Brindisi, Arnaud De Luca, Edouard‐Jules Laforgue, Jean‐Daniel Lalau, Yann Matussiere, Emilie Montastier, Agnès Sallé, Bérénice Segrestin, Valentine Suteau, French Hospital Expert Panel, Sebastien Czernichow, Brigitte Sabatier   +17 more
wiley   +1 more source

Managing atrial fibrillation in the global community: The European perspective. [PDF]

, 2013
Atrial fibrillation is a common, global problem, with great personal, economic and social burdens. As populations age it increases in prevalence and becomes another condition that requires careful chronic management to ensure its effects are minimised ...
Camm, AJ, Kaba, RA, Sharma, R, Williams, TM   +3 more
core   +1 more source